2.Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors（2018）3.CSF-1R Inhibitor Development: Current Clinical Status（2017）4.Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or ...
文献54-早期长期使用CSF1R抑制剂PLX3397可以清除小胶质细胞,并减少5XFAD小鼠阿尔茨海默病模型中神经元内淀粉样蛋白的积累、神经元斑块的沉积以及前纤维化寡聚物的形成 文章题目:Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neur...
[6] Spangenberg E, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal p...
2023 AACR: CT025 - NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience责任编辑 | 有点小吴聊 声明本资讯旨在帮助...
Abbisko Therapeutics Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib(ABSK021) 9 April 2024, Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (...
CSF1R inhibitor is administered via oral route, typically twice daily on an empty stomach, at least one hour before or two hours after food. CSF1R inhibitors work in the following ways: They belong to a class of medications called “kinase inhibitors” that work by slowing or stopping the ...
顺便提一下,文章称他们的分子为switch-control kinase inhibitor,他们之前有一个上市的KIT抑制剂Ripretinib (DCC-2618),也称为switch-control kinase inhibitor,但感觉就是type Ⅱ inhibitor,也许他们的能更有效地将kinase锁定在inactive状态 (文中提到一两处,...
Abbisko Therapeutics Completes the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor -Pimicotinib (ABSK021)in China 28 November 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced the first patient has been do...
PLX5622 is a CSF1R inhibitor (IC50=0.016 µM) with selectivity, oral activity, and blood-brain barrier permeability. PLX5622 induces sustained and specific elimination of microglia. 靶点活性 CSF1R:0.016 µM (IC50), CSF1R:Ki: 5.9 nM ...
CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor ( IC 50 =2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2...